South Korean researchers engineered a new TCR-like bispecific antibody designed to target the PRAME complex as a cancer immunotherapy strategy. The work, published in Cancer Immunology, Immunotherapy, describes laboratory validation intended to broaden immunotherapy access for patients whose tumors express relevant targets. The PRAME complex has been increasingly explored as an immunotherapy handle due to its expression profile in some cancers and its potential to enable tumor recognition through engineered immune binding. This new antibody modality focuses on precision recognition while borrowing structural logic from T-cell receptors. While the report is preclinical, the platform design aims to extend the reach of immunotherapy by creating new tumor-recognition constructs that can recruit immune effector activity through designed binding features.